docetaxel + doxorubicin + cyclophosphamide + paclitaxel

This combination regimen represents standard-of-care chemotherapy for breast cancer, often administered as AC-T (doxorubicin and cyclophosphamide followed by a taxane) or TAC (docetaxel, doxorubicin, and cyclophosphamide). Doxorubicin is an anthracycline that inhibits topoisomerase II and intercalates DNA. Cyclophosphamide is an alkylating agent that forms DNA cross-links. Docetaxel and paclitaxel are taxanes that stabilize microtubules, preventing depolymerization and arresting the cell cycle. In the context of the Phase II trial (NCT06334328) sponsored by the First Hospital of China Medical University, this combination serves as the investigator's choice standard chemotherapy control arm for treating early-stage HR-positive, HER2-low breast cancer.

Other names

TACAC-TTAC/AC-TStandard chemotherapydocetaxel + doxorubicin + cyclophosphamide + paclitaxel-First Hospital of China Medical University-breast cancer